The aim of this study is to evaluate histological changes in tumor-parenchymal interface in clear cell renal cell carcinoma (ccRCC) after neoadjuvant axitinib treatment.
We obtained clinical and pathology materials from 23 ccRCC patients treated with neoadjuvant axitinib in a phase II clinical trial, and from 23 matched patients with ccRCC that had upfront surgery.